Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone

AIDS

Volumn 13, Issue 8, 1999, Pages 957-962

  Altice, Frederick L ^a,b   Friedland, Gerald H ^a   Cooney, Elizabeth L ^a  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretrovirals; CYP3A4; Cytochrome P450; HIV AIDS; Injecting drug users; Methadone; Nevirapine; Non nucleoside reverse transcriptase inhibitor

Indexed keywords

METHADONE; NEVIRAPINE; OPIATE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METHADONE TREATMENT; OPIATE ADDICTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WITHDRAWAL SYNDROME;

ADULT; ANTI-HIV AGENTS; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; NEVIRAPINE; OPIOID-RELATED DISORDERS; RETROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0033044075     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199905280-00012     Document Type: Article

References (33)

1. Autran B, Carcelain G, Li T, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
2. Mounton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers. AIDS 1997, 11:F101-F105.
3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infections and CD4 counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
4. Hogg, RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998, 279:450-454.
5. Palella FJ, Delaney KM, Morrman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
6. Celentano DD, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA 1998, 280: 544-546.
7. Strathdee SA, Palepu A, Cornelisse PGA, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998, 280: 547-549.
8. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with human immunodeficiency virus. Clin Inf Dis 1996, 23:685-693.
9. Schwartz EL, Baechbuhl A, Kahl P, et al. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug using patients with HIV infection. AIDS 1992, 5:619-626.
10. McCance-Katz EF, Jatlow P, Rainey PM, Friedland GH. Methadone effects on zidovudine disposition. J Acquir Immune Defic Syndr 1998, 18:4435-4443.
11. Moody DE, Alburges ME, Parker RJ, Collins JM, Strong JM. The involvement of cytochrome P 450 3A4 in the n-demethylation of 1-alpha-aceylmethadol (LAMM), NorLAMM, and methadone. Drug Metab Dispos 1997, 25:1347-1353.
12. Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampin-induced methadone withdrawal. N Engl J Med 1976, 294:1104-1106.
13. O'Connor PG, Molde S, Henry S, Shockcor WT, Schottenfeld RS. Human immunodeficiency virus infection in injection drug users: a model for primary care. Am J Med 1992, 93:382-386.
14. American Psychiatric Association. Practice guidelines for the treatment of patients with substance abuse disorders: alcohol, cocaine, opioids. Am J Psychiatry 1995, 11 (suppl 152):5-59.
15. Mofat AC (Ed.) Clarke's Isolation and Identification of Drugs in Pharmaceuticals, Body Fluids, and Post-mortem Material. London: The Pharmaceutical Press; 1986.
16. Basalt RC. Disposition of Toxic Drug and Chemicals in Man. New York: Biomedical Publications; 1995.
17. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995, 171:537-545.
18. Hoffman I. A methadone program for addicts with chest disease. JAMA 1970, 211:977-982.
19. Selwyn PA, O'Connor PG, Schottenfeld R. Female drug users with HIV infection: Issues for medical care and substance abuse treatment. In Women and HIV infection. Edited by Minkoff H, Deltovitz J. New York: Raven Press; 1994.
20. Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 1996, 5:1183-1199.
21. Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinetics 1997, 32:194-209.
22. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. Updated Recommendations of the International AIDS Society - USA Panel. JAMA 1998, 280:78-86.
23. Fauci AS, Bartlett JG, Goosby EP, et al. from the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) and the Henry J Kaiser Family Foundation. HHS Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Intern Med 1998, 12:1079-1100.
24. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998, 279:930-937.
25. Centers for Disease Control. Update: Trends in AIDS incidence - United States, 1996. MMWR 1997, 46:861-867.
26. Altice FL, Friedland GH. The era of adherence with HIV therapy [editorial]. Ann Intern Med 1998, 129:503-505.
27. Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS 1997, 11:1665-1670.
28. Alwood K, Keruly J, Moore-Rice K, et al. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. AIDS 1994, 8:1103-1108.
29. Weis SE, Slocum PC, Blais DX, et al. The effect of directly observed therapy on the rates on drug resistance and relapse in tuberculosis. N Engl J Med 1994, 330:1179-1184.
30. Richardson I. Addicts avoid AIDS drugs, fearing they affect methadone. New York Times, Metro Section, July 19 1988, p.23.
31. Ball JC, Lange WR, Myers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatments. J Health Soc Behav 1998, 29:214-226.
32. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users in and out of treatment: An 18-month prospective follow-up. J Acquir Immune Defic Syndr 1998, 6:1049-1056.
33. Boerhinger, Ingleheim. Medical Communications (Roxanne Laboratories). October 12, 1998.